Repligen Stock Analysis
| RGEN Stock | USD 163.63 0.29 0.18% |
Repligen holds a debt-to-equity ratio of 0.23. With a high degree of financial leverage come high-interest payments, which usually reduce Repligen's Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Repligen's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Repligen's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Repligen Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Repligen's stakeholders.
For most companies, including Repligen, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Repligen, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Repligen's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Repligen's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Repligen is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Repligen to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Repligen is said to be less leveraged. If creditors hold a majority of Repligen's assets, the Company is said to be highly leveraged.
Repligen is overvalued with Real Value of 132.54 and Hype Value of 163.63. The main objective of Repligen stock analysis is to determine its intrinsic value, which is an estimate of what Repligen is worth, separate from its market price. There are two main types of Repligen's stock analysis: fundamental analysis and technical analysis.
The Repligen stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Repligen is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Repligen Stock trading window is adjusted to America/New York timezone.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. Repligen Stock Analysis Notes
About 94.0% of the company shares are owned by institutional investors. The book value of Repligen was at this time reported as 37.01. The company has Price/Earnings To Growth (PEG) ratio of 2.59. Repligen last dividend was issued on the 29th of October 2010. Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts. Repligen operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 1852 people. To find out more about Repligen contact Anthony Hunt at 781 250 0111 or learn more at https://www.repligen.com.Repligen Investment Alerts
| The company reported the previous year's revenue of 634.44 M. Net Loss for the year was (25.51 M) with profit before overhead, payroll, taxes, and interest of 365.19 M. | |
| Over 94.0% of the company shares are owned by institutional investors |
Repligen Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 9.19 B.Technical Drivers
As of the 27th of January, Repligen holds the Coefficient Of Variation of 1148.64, risk adjusted performance of 0.0705, and Semi Deviation of 1.75. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Repligen, as well as the relationship between them.Repligen Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Moving Average is predictive technique used to analyze Repligen price data points by creating a series of averages of different subsets of Repligen entire price series.
Repligen Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Repligen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Repligen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Repligen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Repligen Outstanding Bonds
Repligen issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Repligen uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Repligen bonds can be classified according to their maturity, which is the date when Repligen has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Repligen Predictive Daily Indicators
Repligen intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Repligen stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Repligen Forecast Models
Repligen's time-series forecasting models are one of many Repligen's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Repligen's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Repligen Debt to Cash Allocation
As Repligen follows its natural business cycle, the capital allocation decisions will not magically go away. Repligen's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
Repligen currently holds 686.25 M in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. Repligen has a current ratio of 2.25, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Repligen's use of debt, we should always consider it together with its cash and equity.Repligen Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Repligen's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Repligen, which in turn will lower the firm's financial flexibility.Repligen Corporate Bonds Issued
Repligen issues bonds to finance its operations. Corporate bonds make up one of the most significant components of the U.S. bond market and are considered the world's largest securities market. Repligen uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt.
About Repligen Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Repligen prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Repligen shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Repligen. By using and applying Repligen Stock analysis, traders can create a robust methodology for identifying Repligen entry and exit points for their positions.
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts. Repligen operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 1852 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Repligen to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Comparator Now
Portfolio ComparatorCompare the composition, asset allocations and performance of any two portfolios in your account |
| All Next | Launch Module |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repligen. If investors know Repligen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repligen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Repligen is measured differently than its book value, which is the value of Repligen that is recorded on the company's balance sheet. Investors also form their own opinion of Repligen's value that differs from its market value or its book value, called intrinsic value, which is Repligen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repligen's market value can be influenced by many factors that don't directly affect Repligen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repligen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repligen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repligen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.